1,809 Thermo Fisher Scientific Inc. $TMO Shares Bought by Generali Asset Management SPA SGR

Generali Asset Management SPA SGR lifted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 9.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 20,259 shares of the medical research company’s stock after purchasing an additional 1,809 shares during the period. Generali Asset Management SPA SGR’s holdings in Thermo Fisher Scientific were worth $13,676,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of the company. Tsfg LLC grew its holdings in Thermo Fisher Scientific by 20.4% during the second quarter. Tsfg LLC now owns 112 shares of the medical research company’s stock worth $56,000 after purchasing an additional 19 shares during the period. Renasant Bank raised its stake in Thermo Fisher Scientific by 1.0% in the second quarter. Renasant Bank now owns 1,934 shares of the medical research company’s stock valued at $970,000 after buying an additional 20 shares during the period. Strengthening Families & Communities LLC lifted its position in shares of Thermo Fisher Scientific by 0.4% in the third quarter. Strengthening Families & Communities LLC now owns 4,721 shares of the medical research company’s stock valued at $3,187,000 after buying an additional 21 shares during the last quarter. TCI Wealth Advisors Inc. lifted its position in shares of Thermo Fisher Scientific by 5.4% in the first quarter. TCI Wealth Advisors Inc. now owns 431 shares of the medical research company’s stock valued at $212,000 after buying an additional 22 shares during the last quarter. Finally, Legacy Wealth Managment LLC ID boosted its stake in shares of Thermo Fisher Scientific by 78.6% during the 1st quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock worth $25,000 after acquiring an additional 22 shares during the period. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 420 shares of Thermo Fisher Scientific stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $584.81, for a total value of $245,620.20. Following the completion of the sale, the chief accounting officer owned 2,966 shares in the company, valued at $1,734,546.46. The trade was a 12.40% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Marc N. Casper sold 275 shares of the business’s stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $627.05, for a total transaction of $172,438.75. Following the completion of the sale, the chief executive officer directly owned 123,925 shares of the company’s stock, valued at $77,707,171.25. This represents a 0.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 73,368 shares of company stock worth $43,896,820 over the last ninety days. Corporate insiders own 0.33% of the company’s stock.

Wall Street Analysts Forecast Growth

TMO has been the topic of a number of recent analyst reports. Weiss Ratings raised Thermo Fisher Scientific from a “hold (c+)” rating to a “buy (b-)” rating in a report on Thursday, October 8th. Citigroup lifted their price objective on shares of Thermo Fisher Scientific from $685.00 to $800.00 and gave the stock a “buy” rating in a research report on Friday. Guggenheim assumed coverage on shares of Thermo Fisher Scientific in a report on Thursday, October 15th. They issued a “buy” rating on the stock. Morgan Stanley increased their price objective on shares of Thermo Fisher Scientific from $650.00 to $730.00 and gave the company an “overweight” rating in a research report on Monday, October 12th. Finally, UBS Group restated a “buy” rating and set a $800.00 target price on shares of Thermo Fisher Scientific in a research note on Thursday, October 22nd. Two research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $681.00.

Thermo Fisher Scientific Price Performance

NYSE:TMO opened at $694.49 on Wednesday. The stock has a 50 day simple moving average of $649.32 and a 200 day simple moving average of $551.60. Thermo Fisher Scientific Inc. has a 1-year low of $435.27 and a 1-year high of $705.78.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, October 21st. The medical research company reported $6.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.40 by $0.28. The firm had revenue of $12.14 billion during the quarter, compared to the consensus estimate of $11.95 billion. During the same quarter last year, the firm earned $5.79 earnings per share. The business’s revenue for the quarter was up 9.1% compared to the same quarter last year. On average, research analysts forecast that Thermo Fisher Scientific Inc. will post 25.23 earnings per share for the current year.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc is a global supplier of laboratory products, analytical instruments, reagents, consumables, software and services used in scientific research, healthcare, pharmaceuticals, biotechnology and industrial applications. The company serves customers ranging from academic institutions and government agencies to hospitals, clinical laboratories and pharmaceutical manufacturers.

Its offerings include instruments and systems for genetic analysis, mass spectrometry, chromatography, electron microscopy and materials science, as well as molecular biology reagents, cell culture products, laboratory plastics and research chemicals.